Pulmonary fibrosis and COVID-19

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pathology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in millions of deaths globally.
• Severe SARS-CoV-2 infection can trigger an aggressive inflammatory response in the lungs, potentially leading to respiratory failure.
• A significant concern is the link between COVID-19 and pulmonary fibrosis, characterized by excessive collagen deposition and lung tissue damage.

Purpose of the Study:

• To elucidate the mechanisms by which SARS-CoV-2 infection contributes to pulmonary fibrosis.
• To understand how viral binding to Angiotensin Converting Enzyme (ACE) receptors initiates fibrotic processes.
• To highlight the potential for long-term respiratory complications following COVID-19.

Main Methods:

• Review of current understanding of SARS-CoV-2 pathogenesis in the lungs.
• Analysis of the role of ACE receptor binding in viral-induced inflammation and oxidative stress.
• Examination of the signaling pathways leading to fibroblast activation and extracellular matrix deposition.

Main Results:

• SARS-CoV-2 infection stimulates oxidative stress and inflammation via ACE receptor binding.
• The virus promotes pro-fibrotic factors, leading to fibroblast accumulation and activation.
• This process results in exaggerated extracellular matrix deposition, damaging lung architecture and gas-exchange units.

Conclusions:

• COVID-19 related pulmonary fibrosis can develop even after viral clearance and may lead to irreversible lung damage.
• Symptoms like shortness of breath and exercise intolerance can persist due to loss of lung function.
• Preventive measures, including vaccination, are crucial to mitigate the risk of severe COVID-19 and subsequent pulmonary fibrosis.